This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
by Zacks Equity Research
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.
Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
by Arpita Dutt
Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
Why Did Pfizer (PFE) Stock Pop Today?
by Ryan McQueeney
Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
Top Analyst Reports for Apple, Pfizer & Carnival
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Pfizer (PFE) and Carnival (CCL).
Bristol-Myers Reports Positive Results from Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.
AbbVie's RA Candidate Meets Primary Endpoint in Phase III
by Zacks Equity Research
AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
by Zacks Equity Research
Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
3 Excellent Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.
Bristol-Myers' Opdivo Study Meets Early Success, Stock Up
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval
by Swarup Gupta
The Dow endured significant losses over a holiday-shortened trading week.
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.
Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan
by Zacks Equity Research
Aerie Pharmaceuticals, (AERI) announced that it has commenced phase III study -Mercury 3 in Europe for its pipeline candidate Roclatan 0.02%/0.005%.
Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
by Zacks Equity Research
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.
Pfizer's Acute Leukemia Drug Mylotarg Approved by the FDA
by Zacks Equity Research
Pfizer's (PFE) Mylotarg received FDA nod as a treatment for new or relapsed CD33-positive acute myeloid leukemia.
Key FDA Regulatory Events to Watch Out for in Sep 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?
Why Is Pfizer (PFE) Up 2.5% Since the Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Medicines Company's Infection Drug Vabomere Gets FDA Nod
by Zacks Equity Research
The Medicines Company's (MDCO) infection-resistant antibiotic Vabomere secures a fast FDA approval for urinary tract diseases. The drug is likely to hit the market in fourth-quarter 2017.
Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
by Zacks Equity Research
Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.
Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%
by Zacks Equity Research
Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.
Pfizer Presents Encouraging Eliquis Results in NVAF Patients
by Zacks Equity Research
Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
Biogen Alzheimer's Drug Shows Promise in Long-Term Study
by Zacks Equity Research
Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.